This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Biocept 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Antonino Morales

최고 경영자

US$781.6k

총 보상

CEO 급여 비율	46.8%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3.7yrs
이사회 평균 재임 기간	5.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Antonino Morales 의 보수는 Biocept 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$782k	US$366k	-US$32m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$57k	n/a	-US$3m

보상 대 시장: Antonino 의 총 보상 ($USD 781.63K )은 German 시장( $USD 471.55K ).

보상과 수익: 회사가 수익성이 없는 동안 Antonino 의 보상이 증가했습니다.

CEO

Antonino Morales (67 yo)

less than a year

테뉴어

US$781,631

보상

Mr. Antonino Morales serves as Director of Biocept, Inc., since July 20, 2021 and served as its Interim Chief Financial Officer since February 15, 2022 until June 21, 2023 and serves as its Chief Executive...

리더십 팀

이름	위치	테뉴어	보상	소유권
Antonino Morales	CEO, President & Director	less than a year	US$781.63k	데이터 없음
Darrell Taylor	Chief Legal Officer	1.5yrs	US$773.28k	0% € 0
Soon Hahn	Founder	26.6yrs	데이터 없음	데이터 없음
Rob Walsh	VP & Controller	less than a year	데이터 없음	데이터 없음
Philippe Marchand	Chief Operating Officer	1.4yrs	데이터 없음	데이터 없음
Pavel Tsinberg	Director of Technology Development	5.9yrs	데이터 없음	데이터 없음
David Moskowitz	Vice President of Strategy & Corporate Communications	6.8yrs	데이터 없음	데이터 없음
Veena Singh	Senior Medical Director	8.7yrs	US$441.87k	데이터 없음

3.7yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: B00 의 관리팀은 경험 ( 3.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Antonino Morales	CEO, President & Director	2.1yrs	US$781.63k	데이터 없음
Ivor Royston	Independent Director	13.6yrs	US$65.21k	0.00014% € 2.1
Linda Rubinstein	Independent Director	2.1yrs	US$57.26k	0% € 0
Quyen Dao-Haddock	Independent Director	less than a year	US$13.32k	0% € 0
Marsha Chandler	Independent Vice Chairman of the Board	9.8yrs	US$70.21k	0.000070% € 1.0
Fred Hirsch	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Bruce Gerhardt	Independent Chairman of the Board	12.8yrs	US$67.71k	0.0010% € 15.1

5.9yrs

평균 재임 기간

72yo

평균 연령

경험이 풍부한 이사회: B00 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.

This company is no longer active

Biocept 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Biocept, Inc. Announces Executive Changes

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Recent updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

Biocept, Inc. Announces Executive Changes

Biocept Expects to Receive Non-Compliance Notice Form Nasdaq

No longer forecast to breakeven

Full year 2022 earnings released: US$1.89 loss per share (vs US$0.19 loss in FY 2021)

No longer forecast to breakeven

Forecast to breakeven in 2025

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc. announced delayed 10-Q filing

Biocept Receives Non-Compliance Letter from Nasdaq

Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. announced delayed annual 10-K filing

Investor sentiment improved over the past week

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Biocept, Inc. Implements Covid-19 Testing Program at Select California Community Colleges

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

New 90-day high: €6.05

New 90-day high: €5.10

Biocept, Inc. Enters into Laboratory Services Agreements with Independent Physician Associations

Biocept, Inc. Announces to Receives More Than 150,000 Samples for Covid-19 RT-PCR Testing

Biocept, Inc.'s Target Selector™ Liquid Biopsy Demonstrate High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

New 90-day high: €4.80

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations

Biocept, Inc. Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, Including Cancer Cells

Biocept, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Biocept, Inc. Provides Update on COVID-19 Testing with More than 50,000 Specimens Received

New 90-day low: €3.62

Biocept, Inc. Announces That Highmark Has Made A Positive Coverage Determination on Target Selector Liquid Biopsy

New 90-day low: €3.69

Biocept, Inc. Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More Than 20,000 Specimens Processed

New 90-day low: €3.69

New 90-day low - €3.69

New 90-day low - €0.37

Biocept, Inc. Announces One-For-Ten Reverse Stock Split to Regain Compliance

First half earnings released

New 90-day high - €0.92

Biocept, Inc. to Report Q2, 2020 Results on Aug 12, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령